Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human fibroblast growth factor 9 proteoliposomes
- Development stage
- Preclinical
- Lead developer
- Wenzhou Medical University
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
Recombinant human fibroblast growth factor 9 (rhFGF9) proteoliposomes is an experimental biologic therapeutic formulation being investigated for the treatment of epilepsy. The drug consists of the recombinant human FGF9 protein encapsulated in proteoliposomes, a specialized lipid-based delivery system designed for intranasal administration. This route is intended to bypass the blood-brain barrier and deliver the therapeutic protein directly to the central nervous system. FGF9 plays a critical role in the survival of GABAergic neurons and the regulation of GABA expression. Research indicates that a deficiency in FGF9 leads to a GABA/glutamate imbalance, which is a key driver of seizure activity. Preclinical studies conducted by Wenzhou Medical University have demonstrated that rhFGF9 proteoliposomes can significantly reduce seizure frequency in mouse models by activating fibroblast growth factor receptors (FGFR) and restoring inhibitory neurotransmission.
- Other names
- rhFGF9 proteoliposomesrhFGF-9 proteoliposomesrhFGF 9 proteoliposomesrecombinant human FGF9 proteoliposomesrecombinant FGF9 proteoliposomes
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)FGFR3 (Fibroblast growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on recombinant human fibroblast growth factor 9 proteoliposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human fibroblast growth factor 9 proteoliposomes.